An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers
We made an open label, multicenter, non-comparative study to assess the efficacy and safety of oral gatifloxacin, 400mg PO given once-daily during 7 to 14 days for the treatment of adult outpatients with community-acquired pneumonia at five Brazilian medical facilities. Among the 86 subjects availab...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
|
Series: | Brazilian Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000100007&lng=en&tlng=en |
id |
doaj-682e62078e3141879f10bec2c04c7a2f |
---|---|
record_format |
Article |
spelling |
doaj-682e62078e3141879f10bec2c04c7a2f2020-11-25T03:51:02ZengElsevierBrazilian Journal of Infectious Diseases1678-439171626810.1590/S1413-86702003000100007S1413-86702003000100007An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centersAntonio Carlos Nicodemo0Universidade de São PauloWe made an open label, multicenter, non-comparative study to assess the efficacy and safety of oral gatifloxacin, 400mg PO given once-daily during 7 to 14 days for the treatment of adult outpatients with community-acquired pneumonia at five Brazilian medical facilities. Among the 86 subjects available for clinical evaluation, 84 (98%) were cured. The bacteriological eradication and presumed eradication rate was 98% (52/53) among the 44 (51%) patients who were bacteriologically evaluated. Drug-related adverse events were reported by 27% of the patients, diarrhea being the most frequent, occurring in 12% of patients. Adverse events were considered mild (89%) or moderate (11%). We conclude that a 7-14 day course of gatifloxacin, 400mg PO given once daily is safe and effective for the treatment of community-acquired pneumonia. The drug had a favorable safety profile and a good clinical and bacteriological efficacy.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000100007&lng=en&tlng=enGatifloxacincommunity-acquired pneumoniaBrazil |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Antonio Carlos Nicodemo |
spellingShingle |
Antonio Carlos Nicodemo An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers Brazilian Journal of Infectious Diseases Gatifloxacin community-acquired pneumonia Brazil |
author_facet |
Antonio Carlos Nicodemo |
author_sort |
Antonio Carlos Nicodemo |
title |
An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers |
title_short |
An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers |
title_full |
An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers |
title_fullStr |
An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers |
title_full_unstemmed |
An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers |
title_sort |
open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a brazilian study in five centers |
publisher |
Elsevier |
series |
Brazilian Journal of Infectious Diseases |
issn |
1678-4391 |
description |
We made an open label, multicenter, non-comparative study to assess the efficacy and safety of oral gatifloxacin, 400mg PO given once-daily during 7 to 14 days for the treatment of adult outpatients with community-acquired pneumonia at five Brazilian medical facilities. Among the 86 subjects available for clinical evaluation, 84 (98%) were cured. The bacteriological eradication and presumed eradication rate was 98% (52/53) among the 44 (51%) patients who were bacteriologically evaluated. Drug-related adverse events were reported by 27% of the patients, diarrhea being the most frequent, occurring in 12% of patients. Adverse events were considered mild (89%) or moderate (11%). We conclude that a 7-14 day course of gatifloxacin, 400mg PO given once daily is safe and effective for the treatment of community-acquired pneumonia. The drug had a favorable safety profile and a good clinical and bacteriological efficacy. |
topic |
Gatifloxacin community-acquired pneumonia Brazil |
url |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000100007&lng=en&tlng=en |
work_keys_str_mv |
AT antoniocarlosnicodemo anopenlabelmulticenternoncomparativestudyoftheefficacyandsafetyoforalgatifloxacininthetreatmentofcommunityacquiredpneumoniaabrazilianstudyinfivecenters AT antoniocarlosnicodemo openlabelmulticenternoncomparativestudyoftheefficacyandsafetyoforalgatifloxacininthetreatmentofcommunityacquiredpneumoniaabrazilianstudyinfivecenters |
_version_ |
1724489177997770752 |